Introduction: Leaf extracts of Aegle marmelos are reported to have hypoglycemic and anticancer effects. While a lot of information is available about the antioxidant activity of fruit of A. marmelos not much information is available about the antioxidant activity of the leaf of A. marmelos. Objective: The primary objective if this study was to ascertain the antioxidant activity of leaf extract of A. marmelos (AME). Methods: AME was evaluated for total phenolic content (TPC) and total flavonoid content (TFC) by Folin-Ciocalteau reagent method and by aluminium chloride method, respectively. Antioxidant activity of AME was assessed by FRAP assay, DPPH assay, ABTS cation scavenging activity and by reducing power determination. Results: High levels of TPC and TFC were found in AME which showed antioxidant activity comparable to vitamin C. Significant correlation

Cancer, a group of diseases of unregulated cell proliferation, is a leading cause of death worldwide. More than 80% of compounds which have shown promising effects in preclinical studies could not get through Phase II of clinical trials. Such high attrition rate is due to improper or selective use of preclinical modalities in anticancer drug screening. The various preclinical screening methods available such as in vitro human cancer cell lines, in vivo tumor xenograft model, or genetically engineered mouse model have their respective pros and cons. Scrupulous use of these preclinical screening methods vis-à-vis efficacy of potential anticancer compound with diverse mechanism of action can help in bringing down the rate of failure of anticancer compound at clinical phase. This article provides an insight into the various preclinical methods used in anticancer studies along with their advantages and disadvantages.

No abstract

There found a diversity of regulatory requirement in Semi regulated market. This region consists of mainly thecountries from Asia pacific, Latin America, Eastern Europe, Africa and Gulf countries. Countries from Asia pacificand Gulf have somewhat harmonized their regulatory environment through The Association of Southeast AsianNations (ASEAN) and Gulf Co-operation Council (GCC) organizations, ROW countries yet to be harmonizedregulations in their respective regions.The urgent requirement to rationalize & harmonize regulation was required by instance of rising cost of health care,research & development and to meet the public requirement for safe and efficacious treatments to patient in need.ICH committee has given priority to harmonize the format of reporting data for quality, safety and Efficacy in theapplication dossier.The commercial significance of ROW markets is increasing globally. It is crucial that pharmaceutical companies keepup-to-date with the latest regulatory developments to ensure their place on the ROW market.This paper favors the regulatory processes for gaining marketing authorization in ROW countries in terms oftechnical data requirement for the dossier.